What is Wedbush’s Forecast for ZNTL Q1 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Equities researchers at Wedbush issued their Q1 2026 earnings estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 11th. Wedbush analyst R. Driscoll expects that the company will post earnings per share of ($0.32) for the quarter. Wedbush currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS and Q4 2026 earnings at ($0.33) EPS.

Other equities research analysts have also issued reports about the company. HC Wainwright raised Zentalis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 7th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price objective on shares of Zentalis Pharmaceuticals in a report on Tuesday. Wells Fargo & Company cut their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.20.

Zentalis Pharmaceuticals Trading Up 6.1%

Shares of NASDAQ ZNTL opened at $1.40 on Wednesday. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $4.44. The company has a market cap of $101.00 million, a price-to-earnings ratio of -0.68 and a beta of 1.87. The stock’s 50 day simple moving average is $1.54 and its 200 day simple moving average is $1.45.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.12.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cerity Partners LLC grew its holdings in shares of Zentalis Pharmaceuticals by 58.7% in the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock worth $33,000 after acquiring an additional 7,579 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in Zentalis Pharmaceuticals in the second quarter valued at about $31,000. Alpine Global Management LLC acquired a new stake in Zentalis Pharmaceuticals in the first quarter valued at approximately $48,000. SG Americas Securities LLC lifted its position in shares of Zentalis Pharmaceuticals by 35.3% in the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after buying an additional 8,236 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in Zentalis Pharmaceuticals during the second quarter worth approximately $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.